AbbVie was created in 2013 when Abbott Laboratories spun off its research-based pharmaceutical business. Immunology remains the heart of the company: Humira was for years the world's best-selling drug, and successors Skyrizi and Rinvoq were built to carry the franchise beyond its patent cliff. The Allergan acquisition added Botox and a broader aesthetics and neuroscience portfolio, while oncology rounds out the pipeline. AbbVie pairs this drug engine with one of the higher dividend yields among large pharmaceutical companies.